Upvote
Downvote
Scientist I / II, in Vitro Pharmacology
Share Job
- Suggest Revision
$130,000 a year
Full-time
- Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease.
- Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen CRISPR by Design™ platform for CRISPR-based genetic medicine.
- We are seeking a highly creative, passionate, and motivated individual to join us in our quest to develop the next generation of CRISPR-based therapeutics.
- The candidate should have a passion for characterizing the CRISPR systems that advance our therapeutic programs, focusing on building robust workflows for in vitro pharmacological readouts.
- The role will work collaboratively across interdisciplinary teams, including protein engineers, process sciences, computational biologists, NGS, and disease experts.
Active Job
Updated 16 days agoSimilar Job
Relevance
Active